- Incannex Healthcare has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment
- OSA occurs when the airway at the back of the throat becomes blocked
- As a result, the brain and body become oxygen deprived and the sleeper may wake up multiple times throughout the night
- The upcoming trial will assess the therapeutic benefit of Incannex’s IHL-42X treatment at three different dose levels
- The primary endpoint will a reduction in the apnoea hypopnea index (AHI) compared to the baseline level
- Incannex is up 5.45 per cent on the market and shares are trading for 5.8 cents each
